Form 4: MapLight General Counsel Awarded Equity Compensation

MapLight Therapeutics' General Counsel, Kristopher Hanson, received awards of 27,098 restricted stock units and options for 110,046 shares of common stock.

Summary

• Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., was granted 27,098 Restricted Stock Units (RSUs) and options to purchase 110,046 shares of voting common stock.
• The RSUs represent a contingent right to receive one share of common stock each, with a vesting schedule of 1/4th on October 1, 2026, and 1/16th quarterly thereafter.
• The stock options have an exercise price of $17 per share and an expiration date of October 26, 2035, with a vesting schedule of 1/4th on October 1, 2026, and 1/48th monthly thereafter.
• These awards were made on October 27, 2025, and are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a key executive, which is generally positive for aligning management incentives with shareholder interests. It does not contain any negative news or significant market-moving information, hence a moderately positive sentiment.

Positives

• The equity awards align the interests of the General Counsel, Kristopher Hanson, with those of the company's shareholders.
• The grants are part of a standard compensation package, indicating continued commitment from key management personnel.

Risks

• The value of the equity awards is subject to the future performance of MapLight Therapeutics' stock price.
• Vesting of the awards is contingent upon Kristopher Hanson's continued service to the company.

Future Outlook

The vesting schedules for both the Restricted Stock Units and employee stock options extend several years into the future, indicating an expectation of continued service from the General Counsel and long-term alignment with company performance.

Management Comments

• Kristopher Hanson, as General Counsel, received equity awards designed to align his interests with those of the company's shareholders and incentivize long-term performance.

Industry Context

The granting of Restricted Stock Units and stock options to key executives like the General Counsel is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and motivate talent by linking compensation to company performance and shareholder value creation.

Comparison to Industry Standards

• The structure of these equity awards, including vesting schedules and the use of both RSUs and stock options, is consistent with typical executive compensation packages observed across the biotech and broader technology sectors.
• Comparable companies often utilize similar long-term incentive plans to ensure executive retention and performance alignment, such as those seen at early-to-mid-stage biopharmaceutical firms like Sage Therapeutics or Alnylam Pharmaceuticals, where equity forms a significant portion of executive compensation.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the General Counsel's long-term interests with shareholder value creation, potentially leading to more focused management decisions.
• Employees: This filing pertains to a specific executive's compensation and does not directly impact the broader employee base, though it reflects standard executive incentive practices.

Next Steps

• Vesting of 1/4th of the Restricted Stock Units on October 1, 2026.
• Vesting of 1/4th of the employee stock options on October 1, 2026.
• Subsequent quarterly vesting of RSUs and monthly vesting of stock options as per the defined schedules.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Kristopher Hanson, Form 4, Restricted Stock Units, Stock Options, Insider Transaction, General Counsel, Equity Compensation